Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-07-01 Capital/Financing Update
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2020
Capital/Financing Update Classification · 98% confidence The document is a 'Company announcement' from Orphazyme A/S dated July 1, 2020. The core subject is the confidential submission of a draft registration statement on Form F-1 to the SEC for a potential registered public offering in the United States. This action directly relates to fundraising, capital structure changes, and preparing for a public offering (likely an IPO or secondary offering). This aligns best with the 'Capital/Financing Update' category (CAP). Although it mentions SEC filing, it is an announcement *about* the filing process, not the final prospectus or a standard periodic report like 10-K or IR. Given the context of a 'potential registered public offering,' CAP is the most specific fit over the general 'RNS' fallback.
2020-07-01 English
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
Regulatory Filings Classification · 95% confidence The document is a company announcement from Orphazyme A/S detailing topline results from a Phase 2 clinical trial for their drug candidate, arimoclomol. It provides specific clinical data, trial methodology, and management commentary regarding the results. While it mentions an upcoming investor call, the primary purpose of the document is to release the clinical trial findings to the public and shareholders. This fits the definition of a Regulatory Filing (RNS) as it is a formal company announcement regarding material business developments (clinical trial results) that does not fall into more specific categories like a full financial report or a standalone transcript.
2020-06-24 English
Earnings Release 2020
Earnings Release Classification · 95% confidence The document is explicitly titled 'Company announcement' from Orphazyme A/S, dated June 24, 2020, and provides topline results from a phase 2 clinical study. It details scientific findings, patient numbers, endpoints, and adverse events related to the drug arimoclomol. This structure is characteristic of an Earnings Release (ER) or a general announcement of significant operational/clinical progress. Since it focuses on announcing the results of a clinical trial rather than a periodic financial summary (like 10-K or IR), 'Earnings Release' (ER) is the most appropriate fit among the provided options for a major operational update, even though it's clinical data, as it serves the function of informing investors about recent performance/progress. The document also announces a conference call to discuss these results, which is typical for an ER. FY 2020
2020-06-24 English
Major shareholder announcement
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in share ownership (Novo Holdings A/S falling below the 5% threshold). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-05-29 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "Major shareholder announcement" and details a change in shareholding percentage by Novo Holdings A/S, stating they now hold shares corresponding to less than 5% of the total share capital. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2020-05-29 English
Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the initiation of a rolling submission for a New Drug Application (NDA) with the FDA. It provides details on the drug candidate, regulatory designations, and future expectations. While it contains substantive information, it is structured as a standard corporate press release/regulatory announcement. Since it does not fit into specific categories like financial reports, board changes, or shareholder voting, and serves as a general corporate update, it is classified as a Regulatory Filing (RNS).
2020-05-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.